.jpg "Theravance Biopharma (NASDAQ: TBPH)")
Today, the EVP, Gen. Counsel, Secretary of Theravance Biopharma (NASDAQ: TBPH), Bradford Shafer, sold shares of TBPH for $336.4K.
In addition to Bradford Shafer, 2 other TBPH executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Theravance Biopharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $8.32 million and GAAP net loss of $65.09 million. In comparison, last year the company earned revenue of $3.09 million and had a GAAP net loss of $65.32 million. Currently, Theravance Biopharma has an average volume of 232.7K. The Company has a Price to Book ratio of 20.2403.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.75, reflecting a -45.2% downside.
In the last 30 days, insiders have sold $1.1M worth of TBPH shares and purchased $22.54K worth of TBPH shares. The insider sentiment on Theravance Biopharma has been neutral according to 68 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.
Bradford Shafer’s trades have generated a 31.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
